G. Ml and D. Rh, Antifungal serum concentration monitoring : an update, J of Antimicrob Chemother, vol.61, pp.17-25, 2008.

K. F. and E. Mhh, Role of thérapeutic drug monitoring of voriconazole in the treatement of invasive fungal infections, Can J Hosp Pharm, vol.62, issue.6, pp.469-482, 2009.

L. A. Thompson and . Gr, Update on the optimal use of voriconazole for invasive fungal infections, Infection and Drug Resistance, vol.4, pp.43-53, 2011.
DOI : 10.2147/IDR.S12714

C. D. , B. Jp, and D. Gentile-l, Les moisissures d'intérêt médical, Bioforma, p.160, 2002.

B. Sm, . Free, and . Sj, The structure and synthesis of the fungal cell wall, BioEssays, vol.28, pp.799-808, 2006.

B. Mf, Caractérisation de la protéine Knr4 et recherche de ses partenaires fonctionnels pour la compréhension de son rôle dans la synthèse pariétale chez la levure Saccharomyces cerevisiae, Thèse de doctorat, p.9, 2012.

S. M. Maschmeyer-g, Pharmacology and metabolism of voriconazole and posaconazole in the treatement of invasive aspergillosis-Review of the literature, Eur J Med Res, vol.16, pp.139-144, 2011.

I. Pasteur, L. Unité-des-aspergillus, and . Jp, Les différentes formes d'aspergilloses [en ligne] Disponible sur, 2012.

C. Mf, I. F. , and M. C. , Radiologic aspect of acute invasive pulmonary aspergillosis in 18 immunocompromised patients, J radiol, vol.67, issue.5, pp.381-390, 1986.

W. T. Anaissie-e and . W. Denning-d, Treatement of aspergillosis : clinical practice guidelines of infectious diseases society of America, CID, vol.2008, issue.1, pp.46327-360

R. La, R. E. , and G. T. , Pulmonary resection for invasive Aspergillus infections in immunocompromised patients, J Thorac Cardiovasc Surg, vol.109, pp.1182-97, 1995.

C. De-lacerda, . Jm, and . Do, Follow-up of anti- Aspergillus IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis, J Clin Lab Anal, vol.16, issue.3, pp.156-62, 2002.

H. Necker, E. Malades, P. Unité-de-mycologie-parasitologie,-service-de-microbiologie, and . M. Bougnoux, Outils diagnostiques des infections fongiques invasives [en ligne]. Disponible sur : http://www.infectiologie.com/site/medias/enseignement/seminaires_desc, p.9, 2011.

E. M. Doghmi-k and F. T. , Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia : A case treated with voriconazole and caspofungin, Ann Biol Clin, vol.63, issue.4, pp.423-430, 2005.

M. Dj and . Mejicano-gc, Vertebral osteomyelitis due to Candida species: case report and literature review, Clin Infect Dis, vol.33, pp.523-553, 2001.

T. A. Candidose-bronchopulmonaire, Disponible sur : http://www.respir.com/doc, Candidose.asp, 2012.

P. Jr, Azoles : back to the future, Curr. Opin. Infect. Dis, vol.24, issue.suppl2, pp.41-58, 2011.

B. F. Voss-a and . W. Van-hamersvelt-h, Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole, Clin microbiol infect, vol.9, pp.750-753, 2003.

D. Mc, Human fusariosis, Clin Microbiol Infect, vol.10, issue.S1, pp.67-75, 2004.

P. Pg, The role of azoles in the treatement of invasive mycoses : review of the infectious diseases society of America guidelines. Current opinion in infectious deseases, pp.1-13, 2011.

M. O. Traitements, In : communications scientifiques, Edition MAPAR, 2000.

L. Re, Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy, Curr. Opin. Infect. Dis, vol.24, issue.suppl2, pp.14-29, 2011.

B. C. Becavin-m.-a and . Dehaynin-e, Vfend® (voriconazole) [en ligne] Disponible sur : https://www.pharmaweb.univ-lille2.fr/apache2- default/heberges, p.9, 2003.

J. Lb and K. Ca, Voriconazole : a new triazole antifungal agent, Clin. Infect. Dis, vol.36, pp.630-637, 2003.

D. Aes, L. R. , and L. Jr, Pharmacology of systemic antifungal agents, Clin. Infect. Dis, vol.43, issue.1, pp.28-39, 2006.

L. A. , N. Ph, and C. M. , Molecular targeted treatments for fungal infections : the role of drug combinations. Trends in molecular medecine, pp.269-276, 2003.

K. Mo, L. I. , and M. Pa, Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies, Antimicrob Agents Chemother Mar, vol.53, pp.935-944, 2009.

J. Lb and K. Ca, Voriconazole: a new triazole antifungal agent, Clin Infect Dis, vol.36, pp.630-637, 2003.

M. V. , L. Guillou-jl, and L. C. , Serum voriconazole levels following administration via percutaneous jejunostomy tube, Antimicrob. Agents Chemother, vol.47, p.3375, 2003.

L. A. Thompson and . Gr, Update on the optimal use of voriconazole for invasive fungal infections, Infection and Drug Resistance, vol.4, pp.43-53, 2011.
DOI : 10.2147/IDR.S12714

S. Jb, G. P. , and C. R. , Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis, Antimicrob. Agents Chemother, vol.48, p.1065, 2004.

P. Jc, P. F. , and R. J. , Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis : report of a case with successful outcome, Intensive Care Med, vol.32, pp.939-979, 2006.

H. Sm, M. Wf, and . Holz-er, Determination of vitreous, aqueous, and plasma concentration of orally administrated voriconazole in humans, Arch. Ophtalmol, vol.122, pp.42-49, 2004.

A. Hr and G. Mh, Has the era of individualised medecine arrived for antifungal? A review og antifungal pharmacogenomics, Bone Marrow Transplantation, vol.2011, pp.1-14

L. Re, Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy, Curr Opin Infect Dis, vol.24, issue.2, pp.14-29, 2011.

A. D. and P. A. Marchetti-o, Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications, Antimicrob Agents Chemother, vol.53, pp.24-34, 2009.

P. Ac, X. Mo, and A. H. , Voriconazole therapeutic drug monitoring: focus on safety, Expert Opin Drug Saf, vol.9, issue.1, pp.125-137, 2010.

P. Mp and L. Tp, Steady-state plasma pharmacokinetics of oral voriconazole in obese adults, Antimicrob Agents Chemother, vol.55, issue.6, pp.2601-2606, 2011.

K. E. Kraft-s and S. J. Nagel, Evaluation of the effect of obesity on voriconazole serum concentrations, J Antimicrob Chemother, 2012.

C. Pfizer and . Inc, Monographie de produit : Vfend®, p.76, 2010.

P. G. Kauffman-ca and A. D. , Clinical Practice Guidelines for the Management of Candidiasis : 2009 Update by the Infectious Diseases Society of America, Clin Infect Dis, vol.48, pp.503-538, 2009.

P. A. and C. T. Bolay-s, Voriconazole Therapeutic Drug Monitoring in Patient with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clin Infect Dis, vol.46, pp.201-212, 2008.

N. M. Rushing-t and . Kovacs-a, Voriconazole pharmacokinetics and pharmacodynamics in children, Clin Infect Dis, vol.50, issue.1, pp.27-36, 2010.

D. Dw and R. P. Milpied-n, Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis, Clin Infect Dis, vol.34, issue.5, pp.563-71, 2002.

T. K. Brayshaw-n and . Tomaszewski-k, Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, J Clin Pharmacol, vol.46, issue.2, pp.235-278, 2006.

I. A. Schaer-dj and . Schanz-u, Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring, Swiss Med Wkly, vol.136, pp.45-46739, 2006.

Z. Di, . J. Gea-banacloche, and . Childs-r, Hallucinations during voriconazole therapy, Clin Infect Dis, vol.47, issue.1, pp.7-10, 2008.

H. A. Dailly-e and . Le, Level of Evidence for Therapeutic Drug Monitoring of Voriconazole, Therapie, vol.66, issue.2, pp.109-114, 2011.

P. W. Kim-nh and L. Sh, The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial Epub ahead of print, Clin Infect Dis, 2012.

S. J. Safdar-n and . Knasinski-v, Voriconazole therapeutic drug monitoring, Antimicrob Agents Chemother, vol.50, issue.4, pp.1570-1572, 2006.

D. Mj, R. J. , and C. Sc, Multicenter study of voriocnazole pharmacokinetics and therapeutic drug monitoring, Antimicrob Agents Chemother, vol.56, issue.9, pp.4793-4802, 2012.

T. Sm, Y. Pr, and . Scheetz-mh, Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation, Antimicrob Agents Chemother, vol.53, issue.5, pp.1793-1799, 2009.

D. Ashley and E. , Pharmacoeconomics of antifungal therapy: current considerations, Current Opinion in Infectious Diseases, vol.24
DOI : 10.1097/01.qco.0000399604.68268.79

S. H. Dupont-b and L. H. , Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis, Am J Med, vol.119, pp.527-544, 2006.

H. T. Edwards-s and . Buchdahl-r, Voriconazole therapy in children with cystic fibrosis, J Cyst Fibros, vol.2005, issue.4, pp.215-220

L. C. and F. De-chauvin-m, Infections dues à Trichosporon spp. et à Geotrichum spp. EMC Maladies infectieuses, pp.97-104, 2005.

T. Y. Cohen-n and D. S. , Effect of antifungal therapy timing on mortality in cancer patients with candidemia, Antimicrob Agents Chemother, vol.54, issue.1, pp.184-90, 2010.

S. Da, K. Moss-rb, and . Vp, Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art : Cystic Fibrosis Foudation Consensus Conference, Clin Infect Dis, vol.37, pp.225-64, 2003.

S. I. Oberwittler-h and . Riedel-kd, Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype, Br J Clin Pharmacol, vol.68, issue.6, pp.906-921, 2009.

T. K. Brayshaw-n and . Tomaszewski-k, Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, J Clin Pharmacol, vol.46, pp.235-243, 2006.